CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...